Form 4: Royalty Pharma EVP Sells Shares Under 10b5-1 Plan

Royalty Pharma's EVP of Research & Investments, Marshall Urist, sold 20,000 Class A Ordinary Shares for approximately $39.32 per share under a pre-arranged 10b5-1 plan.

Summary

• Marshall Urist, Executive Vice President of Research & Investments at Royalty Pharma plc, reported the sale of 20,000 Class A Ordinary Shares.
• The transaction occurred on December 26, 2025, at a weighted average price of $39.319 per share, with individual sales ranging from $39.22 to $39.41.
• The sale was executed pursuant to a Rule 10b5-1 plan adopted by Mr. Urist on September 16, 2025.
• Following this transaction, Mr. Urist directly holds 7,398 Class A Ordinary Shares.
• Indirect holdings include 100,000 Class A Ordinary Shares through Sandy Lamm LLC and 19,020 Class A Ordinary Shares through an IRA.
• Additionally, Mr. Urist and family vehicles control limited partnership interests in RPI US Partners 2019, LP, exchangeable into 2,474,120 Class A Ordinary Shares.
• He also holds Class E Ordinary Shares of Royalty Pharma Holdings Ltd (RPH) exchangeable into 1,356,528 Class A Ordinary Shares, which are subject to vesting conditions.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The filing reports a routine insider share sale executed under a pre-arranged 10b5-1 plan, which is a common practice for executive financial planning and does not inherently signal positive or negative company performance or outlook.

Positives

• The transaction was conducted under a pre-arranged 10b5-1 plan, indicating a scheduled sale for personal financial planning rather than a reaction to new company-specific negative information.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by the market, potentially signaling a lack of confidence, although this is often not the case for routine planned sales.

Risks

• No specific risks were detailed in this Form 4 filing beyond the general market perception associated with insider share sales.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on September 16, 2025, indicating a pre-scheduled sale for personal financial management.

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 plans, are a common occurrence in publicly traded companies. These plans allow executives to sell shares at pre-determined times or prices to avoid accusations of trading on material non-public information, aligning with standard corporate governance practices.

Comparison to Industry Standards

• The use of a 10b5-1 plan for executive share sales is a standard practice across industries, demonstrating adherence to regulatory guidelines for insider trading.
• The volume of shares sold (20,000) by an EVP is not unusually large for a company of Royalty Pharma's market capitalization, suggesting a routine personal financial planning event rather than a significant change in investment thesis.

Related Party Transactions

• Marshall Urist holds indirect beneficial ownership of 100,000 Class A Ordinary Shares through Sandy Lamm LLC and 19,020 Class A Ordinary Shares through an IRA.
• He also holds limited partnership interests in RPI US Partners 2019, LP, and Class E Ordinary Shares of Royalty Pharma Holdings Ltd (RPH) through family vehicles, which are exchangeable into Class A Ordinary Shares.

Stakeholder Impact

• Shareholders may note the insider sale, but given it's under a 10b5-1 plan, it is unlikely to significantly alter their perception of the company's fundamentals or management's confidence.
• No direct impact on employees, customers, suppliers, or creditors is indicated by this filing.

Next Steps

• No specific future actions or milestones are mentioned in this Form 4 filing.

Key Dates

Recommendation

The reported transaction is a pre-planned insider sale under a 10b5-1 plan, which is a routine event for executive financial management. It does not reflect a change in the company's operational performance, strategic direction, or fundamental value. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Royalty Pharma, RPRX, insider transaction, Form 4, share sale, 10b5-1 plan, executive compensation, Marshall Urist